Clinical Trials
3
Active:0
Completed:0
Trial Phases
1 Phases
Phase 1:3
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (100.0%)A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
Phase 1
Recruiting
- Conditions
- Hemostatic DisordersLymphoproliferative DisordersMultiple MyelomaNeoplasmsHematologic DiseasesImmunoproliferative DisordersCardiovascular DiseasesParaproteinemiasNeoplasms, Plasma CellNeoplasms by Histologic Type
- Interventions
- First Posted Date
- 2024-02-21
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- OriCell Therapeutics Co., Ltd.
- Target Recruit Count
- 81
- Registration Number
- NCT06271252
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
OriCAR-017 Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of R/RMM
Phase 1
Recruiting
- Conditions
- Relapsed and/or Refractory Multiple Myeloma
- First Posted Date
- 2023-12-27
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- OriCell Therapeutics Co., Ltd.
- Target Recruit Count
- 83
- Registration Number
- NCT06182696
- Locations
- 🇨🇳
The First Affiliated Hospital College of Medicine Zhejiang University, Hangzhou, Zhejiang, China
🇨🇳Beijing GoBroad Hospital, Beijing, China
🇨🇳The First Affiliated Hospital with Nanjing Medical University, Nanjing, China
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
Phase 1
Recruiting
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2024-04-03
- Lead Sponsor
- OriCell Therapeutics Co., Ltd.
- Target Recruit Count
- 105
- Registration Number
- NCT05652920
- Locations
- 🇨🇳
Peking University Cancer Hospital, Beijing, Beijing, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳The first hospital of Jilin University, Changchun, Jilin, China
News
No news found